Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
1.
Bioorg Med Chem ; 9(8): 2129-37, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11504649

ABSTRACT

Quinolin-2-ones bearing a heteroaryl-piperazine linked by a two carbon chain at the 3- or 4-position were synthesised and evaluated as mixed 5-HT(1B)/5-HT(2A) receptor antagonists. Potent mixed antagonists were obtained with thieno[3,2-c]pyridine derivatives. In this series, compound 2.1 (SL 65.0472) proved to be functional antagonist at both the 5-HT(2A) receptor (rat in vivo 5-HT-induced hypertension model) and the 5-HT(1B) receptor (dog in vitro saphenous vein assay).


Subject(s)
Piperazines/chemical synthesis , Quinolines/chemical synthesis , Receptors, Serotonin/metabolism , Serotonin Antagonists/chemical synthesis , Animals , Dogs , Piperazines/chemistry , Piperazines/pharmacology , Quinolines/chemistry , Quinolines/pharmacology , Rats , Receptor, Serotonin, 5-HT1B , Receptor, Serotonin, 5-HT2A , Receptors, Serotonin/drug effects , Serotonin Antagonists/chemistry , Serotonin Antagonists/pharmacology
2.
J Nat Prod ; 59(12): 1137-42, 1996 Dec.
Article in English | MEDLINE | ID: mdl-8988598

ABSTRACT

Calystegines, polyhydroxy nortropane alkaloids, are a recently discovered group of plant secondary metabolites believed to influence rhizosphere ecology as nutritional sources for soil microorganisms and as glycosidase inhibitors. Evidence is presented that calystegines mediate nutritional relationships under natural conditions and that their biological activities are closely correlated with their chemical structures and stereochemistry. Assays using synthetic (+)- and (-)-enantiomers of calystegine B2 established that catabolism by Rhizobium meliloti, glycosidase inhibition, and allelopathic activities were uniquely associated with the natural, (+)-enantiomer. Furthermore, the N-methyl derivative of calystegine B2 was not catabolized by R. meliloti, and it inhibited alpha-galactosidase, but not beta-glucosidase, whereas the parent alkaloid inhibits both enzymes. This N-methyl analog therefore could serve to construct a cellular or animal model for Fabry's disease, which is caused by a lack of alpha-galactosidase activity.


Subject(s)
Enzyme Inhibitors/isolation & purification , Enzyme Inhibitors/pharmacology , Nortropanes/isolation & purification , Nortropanes/pharmacology , Plants, Medicinal/chemistry , alpha-Galactosidase/antagonists & inhibitors , Bacteria/drug effects , Bacteria/metabolism , DNA, Bacterial/biosynthesis , Glycoside Hydrolases/antagonists & inhibitors , Plant Roots/chemistry , Pseudomonas/drug effects , Pseudomonas/growth & development , Pseudomonas/metabolism , Seeds/chemistry , Sinorhizobium meliloti/drug effects , Sinorhizobium meliloti/growth & development , Sinorhizobium meliloti/metabolism , Solanaceous Alkaloids , Structure-Activity Relationship
4.
J Med Chem ; 37(16): 2602-8, 1994 Aug 05.
Article in English | MEDLINE | ID: mdl-7914541

ABSTRACT

Synthesis and cytotoxicity of the new analogs (11-13) of docetaxel possessing cyclohexyl groups instead of phenyl groups at the C-3' and/or C-2 benzoate positions are described. The C-2 cyclohexanecarboxylate analog of paclitaxel (15) is also synthesized for comparison. The potency of these new taxoids were examined for their inhibitory activity for microtubule disassembly and also for their cytotoxicity against murine P388 leukemia cell line as well as doxorubicin-resistant P388 leukemia cell line (P388/Dox). It is found that 3'-dephenyl-3'-cyclohexyldocetaxel (11) (0.72T) and 2-(hexahydro)docetaxel (12) (0.85T) possess strong inhibitory activity for microtubule disassembly equivalent to docetaxel (0.7T), which is more potent than paclitaxel (1.0T). The results clearly indicate that phenyl or an aromatic group at C-3' or C-2 is not a requisite for strong binding to the microtubules. This finding has opened an avenue for development of new nonaromatic analogs of docetaxel and paclitaxel. 3'-Dephenyl-3'-cyclohexyl-2-(hexahydro)docetaxel (13) (2T) turns out to be a substantially weaker inhibitor. The cytotoxicities of 11-13 against P388 are, however, in the same range that is 8-12 times weaker than docetaxel and 4-6 times weaker than paclitaxel, i.e., 13 shows equivalent cytotoxicity to that of 11 or 12 in spite of much lower microtubule disassembly inhibitory activity. The cytotoxicities of these new taxoids against the P388/Dox cell line are only 2-2.5 times lower than that of docetaxel. The potency of 2-(hexahydro)paclitaxel (15) for these assays is much lower than the docetaxel counterpart 12. The significant loss of activity in vivo against B16 melanoma is observed for 11-13, i.e., 11 is only marginal (T/C = 38% at 20 mg/kg/day), and 12 and 13 are inactive (T/C = 76% and 79%, respectively). This could be ascribed to faster metabolism, faster excretion or other bioavailability problems.


Subject(s)
Antineoplastic Agents, Phytogenic/chemical synthesis , Paclitaxel/analogs & derivatives , Taxoids , Animals , Antineoplastic Agents, Phytogenic/pharmacology , Antineoplastic Agents, Phytogenic/therapeutic use , Docetaxel , Doxorubicin , Drug Resistance , Leukemia P388/drug therapy , Melanoma, Experimental/drug therapy , Mice , Microtubules/drug effects , Molecular Structure , Paclitaxel/chemistry , Paclitaxel/pharmacology , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...